Yu‐Waye Chu

2.2k total citations
43 papers, 1.2k citations indexed

About

Yu‐Waye Chu is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Yu‐Waye Chu has authored 43 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Yu‐Waye Chu's work include CAR-T cell therapy research (19 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and HER2/EGFR in Cancer Research (12 papers). Yu‐Waye Chu is often cited by papers focused on CAR-T cell therapy research (19 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and HER2/EGFR in Cancer Research (12 papers). Yu‐Waye Chu collaborates with scholars based in United States, France and Canada. Yu‐Waye Chu's co-authors include Ronald E. Gress, Veena Kapoor, Sandhya Girish, Philip J. Lucas, Bahram Valamehr, Amita Joshi, Manish Gupta, Bei Wang, Patricia LoRusso and Chi‐Chung Li and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Yu‐Waye Chu

43 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu‐Waye Chu United States	20	774	523	334	261	227	43	1.2k
Bonnie K. Arendt United States	16	407 0.5×	558 1.1×	188 0.6×	563 2.2×	462 2.0×	23	1.3k
KyungMann Kim United States	15	552 0.7×	309 0.6×	118 0.4×	308 1.2×	130 0.6×	22	1.1k
Thomas Köhnke Germany	21	754 1.0×	532 1.0×	159 0.5×	637 2.4×	902 4.0×	46	1.8k
Enkhtsetseg Purev United States	21	755 1.0×	308 0.6×	129 0.4×	768 2.9×	551 2.4×	55	1.6k
Michael Kuehl United States	18	287 0.4×	305 0.6×	274 0.8×	1.1k 4.0×	519 2.3×	46	1.8k
Michael A. Damore United States	16	276 0.4×	284 0.5×	144 0.4×	302 1.2×	131 0.6×	30	775
Khaja Syed United States	8	524 0.7×	311 0.6×	195 0.6×	376 1.4×	635 2.8×	15	1.1k
Yuhong Lu China	19	572 0.7×	456 0.9×	125 0.4×	394 1.5×	282 1.2×	55	1.1k
K. Papadopoulos United States	16	540 0.7×	299 0.6×	121 0.4×	598 2.3×	48 0.2×	56	1.1k
Richard Meagher United States	17	419 0.5×	458 0.9×	32 0.1×	207 0.8×	344 1.5×	44	1.0k

Countries citing papers authored by Yu‐Waye Chu

Since Specialization

Citations

This map shows the geographic impact of Yu‐Waye Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Waye Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Waye Chu more than expected).

Fields of papers citing papers by Yu‐Waye Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu‐Waye Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Waye Chu. The network helps show where Yu‐Waye Chu may publish in the future.

Co-authorship network of co-authors of Yu‐Waye Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Yu‐Waye Chu. A scholar is included among the top collaborators of Yu‐Waye Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu‐Waye Chu. Yu‐Waye Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gutierrez, Martin, Melissa Johnson, David Sommerhalder, et al.. (2022). 727 Interim phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. A760–A760. 1 indexed citations

Mehta, Amitkumar, Umar Farooq, Andy Chen, et al.. (2022). Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. Blood. 140(Supplement 1). 4577–4578. 34 indexed citations

Goodridge, Jode, Ryan Bjordahl, Sajid Mahmood, et al.. (2020). FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma. Blood. 136(Supplement 1). 4–5. 34 indexed citations

Hosseini, Iraj, Kapil Gadkar, Eric Stefanich, et al.. (2020). Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. npj Systems Biology and Applications. 6(1). 28–28. 82 indexed citations

Bjordahl, Ryan, John Goulding, Mochtar Pribadi, et al.. (2020). Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy. Blood. 136(Supplement 1). 5–6. 2 indexed citations

Lovejoy, Alexander F., Hai Lin, David M. Kurtz, et al.. (2019). Changes in circulating tumor DNA levels are associated with treatment response and progression-free survival in relapse/refractory DLBCL subjects.. Journal of Clinical Oncology. 37(15_suppl). 7546–7546. 1 indexed citations

Budde, Lihua E., Laurie H. Sehn, Sarit Assouline, et al.. (2018). Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. Blood. 132(Supplement 1). 399–399. 44 indexed citations

Zhu, Rui, Dan Lü, Yu‐Waye Chu, et al.. (2017). Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies. The AAPS Journal. 19(3). 669–681. 11 indexed citations

Sun, Liping, Peiyin Wang, Robyn Clark, et al.. (2016). Preclinical Characterization of Combinability and Potential Synergy of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody with Chemotherapy and PD-1/PD-L1 Blockade. Blood. 128(22). 4168–4168. 2 indexed citations

10.

Palanca-Wessels, Maria Corinna, Gilles Salles, Myron S. Czuczman, et al.. (2013). Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL). Blood. 122(21). 4400–4400. 15 indexed citations

11.

Bender, Brendan C., Amita Joshi, Yu‐Waye Chu, et al.. (2012). A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 70(4). 591–601. 66 indexed citations

12.

Lu, Dan, Howard A. Burris, Bei Wang, et al.. (2012). Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Current Drug Metabolism. 13(7). 911–922. 30 indexed citations

13.

Shen, Ben‐Quan, Daniela Bumbaca, Ola M. Saad, et al.. (2012). Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism. Current Drug Metabolism. 13(7). 901–910. 92 indexed citations

14.

Palanca-Wessels, Maria Corinna, Ian W. Flinn, Laurie H. Sehn, et al.. (2012). A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood. 120(21). 56–56. 14 indexed citations

15.

Advani, Ranjana H., Daniel Lebovic, Mark W. Brunvand, et al.. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood. 120(21). 59–59. 11 indexed citations

16.

Gupta, Manish, Patricia LoRusso, Bei Wang, et al.. (2011). Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer. The Journal of Clinical Pharmacology. 52(5). 691–703. 56 indexed citations

17.

Chu, Yu‐Waye & Ronald E. Gress. (2008). Murine Models of Chronic Graft-versus-Host Disease: Insights and Unresolved Issues. Biology of Blood and Marrow Transplantation. 14(4). 365–378. 102 indexed citations

18.

Chu, Yu‐Waye, Shoshana Yakar, Derek LeRoith, & Ronald E. Gress. (2004). Insulin-Like Growth Factor I Is a Positive Regulator of Thymic Function.. Blood. 104(11). 732–732. 1 indexed citations

19.

Chu, Yu‐Waye, Sarfraz Memon, Susan O. Sharrow, et al.. (2004). Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood. 104(4). 1110–1119. 83 indexed citations

20.

Chu, Yu‐Waye, Ray Wang, Ingrid Schmid, & Kathleen M. Sakamoto. (1999). Analysis with flow cytometry of green fluorescent protein expression in leukemic cells. Cytometry. 36(4). 333–339. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact